Compare Natera Inc. Common Stock (NTRA) vs Millicom International Cellular S.A. Common Stock (TIGO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Millicom International Cellular S.A. Common Stock — how do they compare? Natera Inc. Common Stock trades at $392.78 (market cap $57.03B), while Millicom International Cellular S.A. Common Stock trades at $81.45 (market cap $13.49B). The key difference: Natera Inc. Common Stock is far larger — about 4.2× Millicom International Cellular S.A. Common Stock's market cap, and Millicom International Cellular S.A. Common Stock pays a 3.73% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Millicom International Cellular S.A. Common Stock for 0 Days on average.
| NTRA | TIGO | |
|---|---|---|
Market Cap | $57.03B | $13.49B |
Volume | 1,131,157 | 1,314,537 |
Sector | Health | Media |
52-Week High | $425.64 | $104.31 |
52-Week Low | $179.42 | $45.81 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $56.18B | $24.53B |
Dividend Yield | — | 3.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
TIGO trades at $79.54, down 0.92% on the day, with a neutral technical signal and key support at $79. The company reported strong 2025 results with $5.82B revenue and $1.32B net income, but 2026 earnings have missed expectations in two of the last three quarters. Recent news highlights its addition to Zacks' Strong Buy list and a consistent $0.75 quarterly dividend.
The stock offers a 12.9% upside to the consensus price target of $89.78, supported by solid profitability and cash flow, but faces risks from earnings volatility and high debt. Analyst sentiment is mixed with a Hold consensus, suggesting cautious optimism amid integration challenges from recent acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Millicom International Cellular S.A. Common Stock
Millicom International Cellular S.A. operates telecommunications and digital services under the Tigo brand across Latin America, providing mobile, fiber broadband, and pay-TV services. The company also offers mobile financial services through its Tigo Money business.
Read more on TIGO →
